background
cell
immunoglobulin
mucin
phosphatidylserin
ps
receptor
mediat
filoviru
entri
cell
interact
ps
virion
express
implic
ebola
viru
ebov
pathogenesi
howev
remain
unclear
whether
due
serv
filoviru
receptor
vivo
other
suggest
induc
cytokin
storm
elicit
cellvirion
interact
use
model
viru
express
ebov
glycoprotein
demonstr
import
viru
receptor
late
vivo
infect
methodologyprincip
find
use
infecti
recombin
vesicular
stomat
viru
express
ebov
glycoprotein
ebov
gprvsv
assess
role
vivo
infect
balbc
interferon
receptor
mice
challeng
ebov
gprvsvgfp
grvsvgfp
grvsv
caus
profound
morbid
mortal
mous
strain
mice
significantli
better
surviv
mice
follow
ebov
gprvsv
challeng
ebov
gprvsv
load
spleen
high
unaffect
express
howev
infecti
viru
serum
liver
kidney
adren
gland
reduc
late
infect
mice
suggest
viru
entri
via
receptor
contribut
viru
load
consist
higher
viru
load
proinflammatori
chemokin
trend
higher
organ
infect
suffici
mice
compar
mice
proinflammatori
cytokin
modestli
affect
assess
role
cell
ebov
gprvsv
pathogenesi
cell
deplet
defici
mice
mice
challeng
viru
deplet
cell
alter
pathogen
consequ
viru
infect
ccbi
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
conclus
studi
provid
evid
late
time
ebov
gprvsv
infect
increas
viru
load
associ
mortal
consist
import
role
receptor
viru
entri
work
suggest
inhibitor
block
interact
may
serv
effect
antivir
reduc
viru
load
late
time
ebov
infect
author
summari
cell
immunoglobulin
mucin
one
number
phosphatidylserin
ps
receptor
mediat
clearanc
apoptot
bodi
bind
ps
surfac
dead
die
cell
envelop
virus
mimic
apoptot
bodi
expos
ps
outer
leaflet
viral
membran
shown
serv
adher
factorreceptor
filovirus
tissu
cultur
limit
studi
investig
role
receptor
vivo
sought
determin
critic
ebola
viru
glycoproteinmedi
infect
use
model
viru
demonstr
loss
express
result
decreas
viru
load
late
infect
significantli
reduc
viruselicit
mortal
find
provid
evid
serv
import
receptor
ebola
viru
vivo
block
interact
may
effect
antivir
strategi
reduc
viral
load
pathogen
late
time
ebov
infect
ccbi
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
maebov
observ
ebov
gprvsv
less
pathogen
mice
compar
control
mice
impact
loss
specif
ebov
express
viru
sinc
wildtyp
vsv
equal
virul
suffici
mice
wide
rang
challeng
dose
importantli
reduc
mortal
observ
virusinfect
mice
associ
lower
viru
load
late
time
point
infect
multipl
tissu
previous
appreci
import
ebov
ccbi
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
replac
lacz
gene
gener
mous
balbc
receptordefici
ifnar
mice
kind
gift
dr
joan
durbin
nyu
langon
ccbi
intern
licens
made
avail
zair
ebolaviru
ebov
one
five
speci
ebolavirus
within
filovirida
famili
ebov
continu
caus
signific
outbreak
subsaharan
africa
case
fatal
rate
high
filovirus
broad
speci
cellular
tropism
except
lymphocyt
cell
within
bodi
thought
support
ebov
infect
replic
histopatholog
studi
ebov
infect
human
nonhuman
primat
nhp
demonstr
viral
antigen
mani
differ
organ
includ
liver
spleen
lymph
node
kidney
adren
gland
lung
gastrointestin
tract
skin
brain
heart
genotyp
refer
throughout
studi
expect
genotyp
produc
normal
mendelian
ratio
genom
dna
mous
tailclip
assess
pcr
genotyp
primer
protocol
ifnar
screen
previous
organ
harvest
control
mice
day
follow
infect
ebov
prior
euthanasia
mice
anesthet
isofluran
perform
retroorbit
bleed
serum
mice
euthan
perfus
ml
pb
heart
organ
harvest
weigh
frozen
determin
viru
titer
organ
sera
thaw
organ
homogen
pb
filter
syring
filter
viral
titer
determin
end
point
dilut
vero
cell
previous
quantit
revers
transcriptas
polymeras
chain
reaction
qrtpcr
use
detect
proinflammatori
cytokin
chemokin
level
organ
mice
challeng
ebov
time
harvest
organ
place
trizol
frozen
use
total
rna
isol
use
trizol
ls
reagent
life
technolog
accord
manufactur
tissu
rna
isol
procedur
rna
quantifi
nanodrop
thermo
scientif
total
rna
revers
transcrib
cdna
use
random
primer
highcapac
cdna
revers
transcript
kit
appli
biosystem
sybr
green
base
quantit
pcr
reaction
appli
biosystem
perform
use
dilut
cdna
reaction
specif
primer
murin
cytokin
chemokin
primer
sequenc
found
supplement
tabl
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
authorfund
examin
wt
vsv
serv
excel
control
vivo
studi
ebov
gprvsv
challeng
control
mice
iu
vsv
iv
inject
contrast
ebov
gprvsv
find
observ
differ
surviv
curv
two
strain
mice
fig
sinc
like
vsv
bear
nativ
gp
pathogen
recombin
vsv
contain
differ
viral
gp
also
evalu
mortal
associ
differ
dose
vsv
found
administr
littl
iu
vsv
lethal
ifnar
mice
supplement
fig
thu
repeat
vsv
infect
control
mice
challeng
dose
iu
determin
subtl
chang
viru
pathogenesi
could
discern
even
low
dose
differ
surviv
mice
versu
control
mice
fig
result
provid
evid
differ
ebov
gprvsv
pathogenesi
balbc
ifnar
mice
due
presenc
ebov
gp
express
recombin
vsv
rather
vsv
gene
reduc
pathogenesi
ebov
gp
express
viru
mice
consist
find
describ
younan
et
al
use
maebov
effect
express
viremia
organ
viral
load
follow
iv
ebov
infect
examin
serum
organ
harvest
day
follow
infect
fig
viremia
infecti
viru
variou
organ
quantifi
endpoint
dilut
titer
vero
cell
highli
permiss
cell
line
ebov
gprvsv
earli
time
ccbi
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
infect
differ
viremia
viru
load
observ
organ
versu
control
mice
howev
day
ebov
infect
mice
reduct
viremia
compar
control
mice
fig
similar
trend
observ
infect
full
length
ebov
gprvsv
supplement
fig
parallel
level
infecti
viru
liver
kidney
adren
gland
also
significantli
reduc
studi
day
infect
also
indic
ebov
load
much
reduc
brain
mice
trend
lower
testi
supplement
fig
day
verifi
cell
within
peripher
blood
profoundli
deplet
day
infect
flow
cytometri
follow
immunostain
mab
fig
observ
cellcompet
mice
studi
celldeplet
control
mice
challeng
ebov
gprvsv
succumb
infect
day
likewis
celldeplet
mice
significantli
better
surviv
cell
deplet
control
mice
exhibit
improv
surviv
mice
celldeplet
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
identifi
express
cell
serv
viral
target
understand
contribut
cell
ebov
diseas
pathogenesi
abl
better
develop
specif
therapeut
ebov
infect
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
ctype
lectin
specif
galactos
nacetylgalactosamin
promot
filoviru
entri
j
virol
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
